In conclusion, we have showed that high CD73 expression is correlated with favorable clinical efficacy of ICIs in patients with EGFR mutation‐positive NSCLC who have developed resistance to EGFR‐TKI treatment. Here, EGFR is linked to non-small cell lung carcinoma.